Navigation Links
The Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing from $460 Million in 2009 to Approximately $610 Million in 2019
Date:11/9/2010

BURLINGTON, Mass., Nov. 9, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the acute ischemic stroke (AIS) drug market will remain relatively flat, increasing from $460 million in 2009 to approximately $610 million in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Acute Ischemic Stroke reveal that, in the forecasted absence of new therapies, drug-treatment rates in AIS will grow modestly as the use of recombinant tissue plasminogen activator (rt-PA; Genentech's Activase, other brands) gradually increases, aided by a recently extended treatment window. Rt-PA, the gold standard of pharmacological treatment in AIS, is administered to only a small fraction (less than 4 percent in 2009) of diagnosed patients in the world's major pharmaceutical markets.

"Broadening the use of rt-PA and interventional therapies such as stroke devices, including Concentric Medical's Merci Retrieval System, coupled with continued improvements in stroke systems of care will be crucial steps in the near-term future of stroke treatment," said Decision Resources Analyst Jonathan Searles. "Given the lingering questions among interviewed thought leaders about mid- and late-stage emerging treatments such as Paion/Lundbeck's thrombolytic desmoteplase and D-Pharm's metal ion chelator DP-b99, and in light of the continual attrition of investigational treatments in stroke, we do not forecast the launch of any novel therapies through 2019, although we continue to monitor several new therapies with great interest."

The findings also reveal that the persistent failure of neuroprotectants in clinical trials underscores physicians' growing skepticism about the promise of acute neuroprotection, particularly in monotherapy. Interviewed neurologists indicate that new directions in neurorestorative therapy that are currently under research offer potentially more promising and much needed avenues for treatment. Although research in this arena suffered a setback with the failure of Stem Cell Therapeutics' NTx-265 in a Phase II clinical study earlier this year, a growing number of companies including ReNeuron, Athersys, SanBio and Stemedica Cell Technologies are preparing for early clinical studies with stem cells, while PhotoThera is continuing to assess its innovative NeuroThera transcranial laser recovery device.

"Significant opportunity exists for effective neurorestorative therapies—treatments that could repair damaged tissue post-stroke to enhance recovery," Mr. Searles said. "This arena represents an untapped clinical and commercial opportunity with game-changing implications if a treatment—drug or device—can demonstrate regenerative effects and is safe and easy to administer."

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.Contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
2. Cheetah Medicals NICOM(R) System for Noninvasive Hemodynamic Monitoring Found to be an Effective Tool for Identification of Acute Heart Failure in the Emergency Department
3. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
4. Awarepoint to Present ZigBee-based Wireless Sensor Networks for Use in Acute Care Hospitals and Beyond at Mobile Health Expo Speaker Session
5. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
6. Daily Intake of Yakult Is Efficacious in Reducing Incidence of Acute Diarrhea in Young Children
7. Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome
8. Intensive Chemotherapy May Be Harmful to Most Older Patients With Acute Myeloid Leukemia
9. Global Acute Coronary Syndrome Industry
10. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
11. An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
Breaking Medicine News(10 mins):